BD Biosciences and StemCell Technologies sign license agreements with WARF to commercialize novel culture media and surfaces for human embryonic stem cell research
The agreements also mark the beginning of a strategic collaboration between BD Biosciences and StemCell Technologies, which aims to provide products that are superior in quality, performance and reliability to facilitate and support the field of stem cell research. The development of these products arises from primary research performed by Dr. James Thomson and Dr. Tenneille Ludwig at the University of Wisconsin – Madison and the WiCell™ Research Institute, a non-profit subsidiary of WARF.
"We are very pleased to be working with both WiCell and BD to further expand the adoption and availability of complete cell environments pre-qualified for our customers' critical research," said Dr. Allen Eaves, President and CEO of StemCell Technologies, Inc. "Through the WARF license and our very productive, collaborative relationships with BD and WiCell, we are confident we have created a solid roadmap to innovation and standardization in the stem cell research field."
"We are energized by this new collaboration with StemCell Technologies and WiCell," added Joseph Gentile, General Manager and Vice President of BD Biosciences – Discovery Labware. "Through this relationship, we aim to provide our customers with the tools to conduct research that one day may address some of today's most debilitating diseases, such as diabetes."
The first commercial products expected from these new license agreements and collaboration are a defined medium and compatible tissue culture surface to support the feeder-independent maintenance of hESC—a major advance in current state-of-the-art cell culture conditions. These products are expected to be introduced to the market on June 18, 2007 at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Cairns, Australia.
Director, Communications and PR
StemCell Technologies Contact:
Dr. Allen Eaves
President and CEO
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
About StemCell Technologies
StemCell Technologies, Inc. is a life sciences company based in Vancouver, British Columbia. StemCell Technologies provides highly specialized cell culture media and cell separation products that support and enable medical research in areas such as cancer, hematology, immunology, cell transplantation, gene therapy, and stem cell biology. More information about StemCell Technologies can be found at www.stemcell.com.
The Wisconsin Alumni Research Foundation supports world-class research at the University of Wisconsin-Madison by protecting the intellectual property of University faculty, staff and students, and by licensing inventions resulting from their work. Established in 1925, WARF was the first university technology transfer office in the United States.
About WiCell™ Research Institute
WiCell is a non-profit subsidiary of WARF that was created to support human embryonic stem cell research on the UW-Madison campus. WiCell's mission is to provide cells to academic scientists all over the world and to engage in research using the scientific expertise of UW-Madison researchers.
This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future performance, products or other events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in healthcare or other governmental regulation; as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.